Clinical trials: Fibrosis Myocardial
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
HIV
Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals.
- Trial name
- NCT02740179
- Testing
- Eplerenone, Lifestyle Modification
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes Mellitus, Myocardial Fibrosis
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
There is an unmet need for Cardiovascular Disease (CVD) risk reduction in patients with Type 2 Diabetes. In recent trials there has been promising findings of more effective glucose management and reductions in overall CVD events…
- Conditions
- Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
- Trial name
- NCT03782259
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Washington
Chagas Disease
Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease
One of the most challenging issues of chronic Chagas disease is to provide earlier detection of heart involvement. Two-dimensional speckle tracking (2-D ST) echocardiography, a new imaging modality with useful applications in…
- Trial name
- NCT02327052
- Testing
- No intervention was performed.
- Where
- Brazil
- Volunteers
- 58 people
- Sponsor
- Hospital Sao Rafael
Congenital Heart Disease, Heart Failure
Spironolactone in Adult Congenital Heart Disease
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function.
- Conditions
- Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
- Trial name
- NCT01069510
- Testing
- Spironolactone 25mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Primary Biliary Cholangitis, Cardiovascular Abnormalities
Early Identification of Myocardial Impairment in PBC
Primary biliary cholangitis (PBC) is a chronic inflammatory liver disease leading to cirrhosis. Researches reported patients with PBC may involve abnormalities on skeleton, thyroid and exocrine glands.
- Trial name
- EARLY-MYO-PBC (NCT03545672)
- Testing
- CMR examination
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common genetic cardiomyopathy and remains the leading cause of sudden cardiac death in young people and an important cause of heart failure symptoms and death at any age.
- Trial name
- NCT00879060
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
End-Stage Renal Disease
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- SPin-D (NCT02285920)
- Testing
- Spironolactone
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Heart Failure, Diastolic, Diastolic Heart Failure
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Unlike heart failure with reduced ejection fraction (HFrEF) where several medicines and devices have been demonstrated to reduce mortality, no such therapies have been identified in HFpEF.
- Conditions
- Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
- Trial name
- HFpEF-PRoF (NCT02589977)
- Testing
- regadenoson
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Marvin W. Kronenberg, M.D.
Tetralogy of Fallot, Transposition of the Great Vessels With an Arterial Switch
The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease
Hypothesis: By blocking aldosterone signaling in patients with Tetralogy of Fallot, Transposition of the great vessels with a prior atrial switch, and single ventricle "Fontan" patients, incident heart failure will be delayed…
- Conditions
- Tetralogy of Fallot, Transposition of the Great Vessels With an Arterial Switch, Single Ventricle With a Fontan Palliation
- Trial name
- NCT01971593
- Testing
- Eplerenone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine